Island Pharmaceuticals Boosts Galidesivir Supply to 800 Courses Amid Escalating Ebola Outbreak

Expanded Galidesivir Inventory Targets Urgent Ebola Outbreak

Island Pharmaceuticals (ASX:ILA) is ramping up its antiviral arsenal with a second manufacturing campaign of GMP-grade Galidesivir, aiming to have 700 to 800 treatment courses ready by the fourth quarter of 2026. This move comes as the Bundibugyo Ebola outbreak in Central Africa accelerates alarmingly, with over 5,200 confirmed cases and nearly 2,500 deaths reported as of mid-August. The outbreak's pace is reportedly five times faster than previous episodes at a similar stage, amplifying the urgency for effective therapeutic options.

Galidesivir, an antiviral with broad-spectrum activity against multiple filoviruses, is positioned as a critical countermeasure in this context. The drug has demonstrated 100% survival in Ebola Zaire non-human primate models when administered 48 hours post-infection, and maintains efficacy even with delayed dosing, a crucial factor given the often late detection of cases in real-world outbreaks.

Strategic Stockpiling Enhances Outbreak and Biodefence Readiness

Rather than manufacturing on a just-in-time basis, Island is deliberately building a substantial inventory of Galidesivir to ensure rapid deployment capabilities. CEO Dr David Foster emphasises that this strategic stockpile not only supports ongoing compassionate use under the World Health Organization’s MEURI framework in Uganda but also strengthens Island’s hand in engaging with governments and biodefence agencies. The availability of a ready supply signals operational readiness and facilitates procurement discussions without delays inherent in initiating new manufacturing runs.

The MEURI deployment expected in Uganda during 2026 offers a rare opportunity to collect prospective human efficacy, safety, and virological data during an active outbreak, complementing the company’s regulatory strategy. This real-world clinical data will augment the existing FDA Animal Rule pathway, which relies on controlled non-human primate efficacy studies, positioning Galidesivir as a multi-filovirus countermeasure with strong commercial and biodefence potential.

Regulatory and Commercial Pathways Underpinning Galidesivir’s Potential

Island’s development program is anchored by pivotal studies targeting Marburg virus using the FDA-preferred Angola strain, with an NDA submission anticipated to commence preparation in the third quarter of 2027. Marburg remains a significant biodefence gap, with no approved antivirals currently in the U.S. Strategic National Stockpile despite substantial government investment exceeding US$600 million.

Galidesivir’s strong efficacy in both Ebola and Marburg primate models, combined with its broad-spectrum activity against more than 20 RNA viruses, including MERS, Zika, and Yellow Fever, enhances its appeal as a biodefence countermeasure. Historical data indicates that Animal Rule approvals often lead to procurement into national stockpiles, with associated Priority Review Vouchers valued at around US$200 million on secondary markets.

Dr Foster highlights that maintaining a meaningful inventory is a critical component of Island’s strategy to accelerate Galidesivir into a revenue-generating antiviral and biodefence asset, capable of rapid deployment in outbreak scenarios and government stockpiling initiatives.